The opening price for QEP Resources, Inc. (NYSE:QEP) was $8.62 and the volume amounted to 4.59 million shares which compares with the average volume of 5.43 million shares. The company stock experienced a -1.14% move to arrive at $8.65.QEP Resources, Inc. (QEP) Analyst Opinion
QEP Resources, Inc. has a consensus outperform rating from 21 Wall Street analysts, and the number of shares currently sold short amount to at least 5.94% of shares outstanding. The stock spiked 0.35% last month and is down -53.01 this year. Wall Street is only getting more bullish on the stock, with 12 of analysts who cover QEP having a buy-equivalent rating. Analysts have placed a $13.45 price target on QEP Resources, Inc., suggesting a 55.49% gain from recent close. It’s currently trading about -59.04% below its 52-week high.
QEP Resources, Inc. (QEP) surprised the stock market in its last reported earnings when it earned -$0.1 a piece versus the consensus-estimated -$0.2. Its revenue totaled $394.95 million up 2.93% from the previous quarter.QEP Resources, Inc. (NYSE:QEP) Intraday View
This stock (QEP) is ahead of its 52-week low with 23.22%. Its last month’s stock price volatility remained 5.28% which for the week stands at 5.69%. The share price has moved backward from its 20 days moving average, trading at a distance of -3.2% and stays 0.75% away from its 50 days moving average. Over the last five days, shares have faced -11.28% losses and now is down -17.38% since hitting its 200-day moving average of $9.05. QEP Resources, Inc. (QEP) has made its way to a 12-month decline of -52.42%.
Turning to Halozyme Therapeutics, Inc. (NASDAQ:HALO), its shares were trading at $18.25 a retreat of $-0.31, on the trading floor. The stock, after opening at $18.43, touched a high of $18.45 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.3. Halozyme Therapeutics, Inc. has 3 buy ratings, 2 holds and 1 sells even after the stock tumbled -5.78% from its high of $19.37 to a $2.65 billion market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 2.2 to 2.2 during a month. Analysts set a 12-month price target of $20.6 a share. The target implies a 12.88% spike from where the shares are currently trading. Also, the current price highlights a discount of 80.82% to analysts’ high consensus price target.Halozyme Therapeutics, Inc. (NASDAQ:HALO) Intraday Trading
The counter witnessed a trading volume of 0.97 million shares versus an average volume of 1.4 million shares during last trading session. Its last month’s stock price volatility remained 4.18% which for the week approaches 3.82%. The lowest price the stock reached in the last trading day was $18.13 and compares with the $9.68 52-week low. The stock recovered 88.53% since its low point and has performed 84.72% year-to-date.